Public trial registry of the CCC-Munich

Trial AGO-Ovar 17

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
AGO-Ovar 17
World
Full title
:

A prospective randomized Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer.
The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) Trial

World
Description
:

Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIb - IV (all grades and all histological types) epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC) with indication for a platin/paclitaxel chemotherapy

World
EudraCT number
:
World
Responsible organization
:
Lmu
Indications
Classification Code Description
ICD-10-GM C56 Bösartige Neubildung des Ovars
ICD-10-GM C57.- Bösartige Neubildung sonstiger und nicht näher bezeichneter weiblicher Genitalorgane
ICD-10-GM C78.6 Sekundäre bösartige Neubildung des Retroperitoneums und des Peritoneums
Trial design
World
Blinding type
:
Open
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Positive
World
BfArM - vote
:
Positive
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy line
:
1
Participants The lead of this trial has not explicitely given their approval for publishing the contact information of the principal investigators or specific contact persons.